A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Active:	Yes
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT05787587
Trial Phases:	Phase I	Protocol IDs:	IDE161-001 (primary) NCI-2023-03139
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	IDEAYA Biosciences
NCI Full Details:	http://clinicaltrials.gov/show/NCT05787587

Summary

The purpose of this study is to characterize the safety, tolerability, and efficacy of
IDE161.

Objectives

The purpose of this study is to characterize the safety, tolerability including determination
of maximum tolerated dose (MTD), maximum accepted dose (MAD), recommended dose(s) for
expansion (RDE) and/or recommended Phase 2 dose (RP2D), pharmacokinetics (PK),
pharmacodynamics (PD) and preliminary anti-tumor activity of IDE161 as a single agent in
participants with advanced or metastatic solid tumors harboring BRCA1/2 loss of function
alterations and/or other defects in the homologous recombination (HR) pathway.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.